Table 1 Comparison of patients’ baseline data between 2 groups
Methylene blue group | Coil group | P value | |
|---|---|---|---|
Patients number | 15 | 16 | - |
Age (years) | 61 (Q1: 50; Q3: 68) | 55 (Q1: 48; Q3: 64) | 0.489 |
Gender | 0.576 | ||
Male | 6 | 8 | |
Female | 9 | 8 | |
Previous tumor history | 1 | 2 | 1.000 |
Emphysema | 1 | 0 | 0.484 |
Tumor marker levels | |||
Neuronspecific enolase (U/ml) | 12.3 (Q1:11.6; Q3: 13.2) | 12.1 (Q1:10.7; Q3: 13.7) | 0.58 |
Carcinoembryonicantigen (ng/ml) | 1.9 (Q1:1.6; Q3: 3.2) | 1.5 (Q1:1.3; Q3: 2.3) | 0.205 |
Squamouse cell carcinoma antigen (μg/L) | 1 (Q1:0.8; Q3: 1.6) | 1.2 (Q1:0.6; Q3: 1.6) | 0.751 |
Cyfra21-1 (ng/ml) | 2.1 (Q1:1.5; Q3: 2.6) | 1.6 (Q1:1.2; Q3: 2.6) | 0.372 |